The efficacy of montelukast as a protective agent against 131I-induced salivary gland damage in rats: scintigraphic and histopathological findings
暂无分享,去创建一个
S. Kuru | G. Koca | K. Demirel | M. Korkmaz | S. S. Gültekin | Ünsal Han
[1] E. Kose,et al. Beneficial Effects of Montelukast Against Methotrexate-Induced Liver Toxicity: A Biochemical and Histological Study , 2012, TheScientificWorldJournal.
[2] Jilly F. Evans,et al. International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions , 2011, Pharmacological Reviews.
[3] C. Feldman,et al. Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist? , 2010, TheScientificWorldJournal.
[4] H. Hoeffken,et al. Scintigraphic assessment of salivary gland function in a rat model. , 2010, In vivo.
[5] U. Topaloglu,et al. Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. , 2010, The Journal of surgical research.
[6] G. Bugdayci,et al. Montelukast protects axial pattern rat skin flaps against ischemia/reperfusion injury. , 2009, The Journal of surgical research.
[7] J. Weiss,et al. History and development of radiation-protective agents , 2009, International journal of radiation biology.
[8] W. Oyen,et al. Guidelines for radioiodine therapy of differentiated thyroid cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[9] G. Rovati,et al. Cysteinyl-Leukotriene Receptors and Cellular Signals , 2007, TheScientificWorldJournal.
[10] M. Thompson,et al. Cysteinyl‐leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends , 2007, Medicinal research reviews.
[11] G. Şener,et al. Montelukast reduces ischaemia/reperfusion‐induced bladder dysfunction and oxidant damage in the rat , 2007, The Journal of pharmacy and pharmacology.
[12] B. Yeğen,et al. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist. , 2007, European journal of pharmacology.
[13] C. Harmer,et al. Salivary gland toxicity after radioiodine therapy for thyroid cancer. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).
[14] J. Franklyn,et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. , 2007, The Journal of clinical endocrinology and metabolism.
[15] S. Holgate,et al. Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts. , 2007, The Journal of allergy and clinical immunology.
[16] G. Riccioni,et al. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. , 2006, Current medicinal chemistry.
[17] Chi-Yuan Li,et al. Effects of leukotriene receptor antagonists on monocyte chemotaxis, p38 and cytoplasmic calcium , 2006, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[18] A. Khan,et al. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy , 2006, Nuclear medicine communications.
[19] S. Gültekin,et al. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer , 2006, Nuclear medicine communications.
[20] J. Franklyn,et al. : 131 I Activity for Remnant Ablation in Patients with Differentiated Thyroid Cancer : A Systematic Review , 2006 .
[21] B. Yeğen,et al. Leukotriene receptor blocker montelukast protects against burn-induced oxidative injury of the skin and remote organs. , 2005, Burns : journal of the International Society for Burn Injuries.
[22] A. Vissink,et al. On the mechanism of salivary gland radiosensitivity. , 2005, International journal of radiation oncology, biology, physics.
[23] T. Ichiyama,et al. Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[24] D. Rades,et al. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[25] 喜多 保. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma , 2004 .
[26] L. Jenicke,et al. [Histomorphologic and salivary gland scintigraphic findings in radiation-induced sialadenitis due to fractionated irradiation of the head and neck region of rats. A model for evaluating potentially radioprotective substances]. , 2004, HNO.
[27] L. Jenicke,et al. Histomorphologische und sialoszintigraphische Befunde zur Radiosialadenitis unter fraktionierter Bestrahlung der Kopf-Hals-Region von Ratten , 2004, HNO.
[28] R. Nagler. Effects of head and neck radiotherapy on major salivary glands--animal studies and human implications. , 2003, In vivo.
[29] L. Jenicke,et al. Investigation of radiosialadenitis during fractioned irradiation: sialoscintigraphical and histomorphological findings in rats , 2003, European Archives of Oto-Rhino-Laryngology.
[30] S. Terakawa,et al. Secretion of Saliva in X-Irradiated Rat Submandibular Glands , 2003, Radiation research.
[31] S. Mandel,et al. Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.
[32] M. Tuncel,et al. Scintigraphic Evaluation of Salivary Gland Dysfunction in Patients with Thyroid Cancer After Radioiodine Treatment , 2002, Clinical nuclear medicine.
[33] June-Key Chung,et al. Sodium iodide symporter: its role in nuclear medicine. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] F. Metternich,et al. Studies on the radioprotective potency of amifostine on salivary glands of rats during fractionated irradiation: acute and late effects , 2003, European Archives of Oto-Rhino-Laryngology.
[35] R. Solans,et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] C. Spitzweg,et al. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. , 1999, The Journal of clinical endocrinology and metabolism.
[37] J. Bidart,et al. Immunohistochemical analysis of Na+/I- symporter distribution in human extra-thyroidal tissues. , 1999, European journal of endocrinology.
[38] C. Kirsch,et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[39] F. Mishkin. Radionuclide salivary gland imaging. , 1981, Seminars in nuclear medicine.
[40] N. B. Myant,et al. Concentration of salivary iodide: a comparative study , 1959, The Journal of physiology.
[41] E. Pochin. [Radioiodine in the treatment of thyroid cancer]. , 1957, Recenti progressi in medicina.